Cervical Cancer

>

Latest News

Simple Hysterectomy Deemed Noninferior to Radical Version in Low-Risk, Early-Stage Cervical Cancer
Simple Hysterectomy Deemed Noninferior to Radical Version in Low-Risk, Early-Stage Cervical Cancer

June 2nd 2023

Canadian study results indicate surgical de-escalation is possible in patients with low-risk, early-stage cervical cancer.

Toripalimab, Bevacizumab, and Chemo Elicits Responses in Refractory, Recurrent, or Metastatic Cervical Cancer
Toripalimab, Bevacizumab, and Chemo Elicits Responses in Refractory, Recurrent, or Metastatic Cervical Cancer

March 27th 2023

Cervical Cancer Awareness Month: Dramatic Increase in Cervical Cancer Research Is Driving Treatment Progress
Cervical Cancer Awareness Month: Dramatic Increase in Cervical Cancer Research Is Driving Treatment Progress

January 16th 2023

Long-Term Follow-Up Confirms Survival Benefit from Second-Line Cemiplimab for Recurrent/Metastatic Cervical Cancer
Long-Term Follow-Up Confirms Survival Benefit from Second-Line Cemiplimab for Recurrent/Metastatic Cervical Cancer

September 11th 2022

Is PD-L1 an Appropriate Biomarker in Cervical Cancer?
Is PD-L1 an Appropriate Biomarker in Cervical Cancer?

August 23rd 2022

More News

Adding Pembrolizumab Extends OS and PFS in Key Subgroups in Recurrent, Metastatic Cervical Cancer

Adding Pembrolizumab Extends OS and PFS in Key Subgroups in Recurrent, Metastatic Cervical Cancer

Tony Berberabe, MPH
June 6th 2022

Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.

Read More